New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced that new preclinical data for EDP-235, its lead oral protease inhibitor for COVID-19, will be presented at the ISIRV-WHO Virtual Conference from October 19-21, 2021. The poster presentation titled “EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19” will be showcased on October 19 at 8:00 a.m. CET, presented by Li-Juan Jiang, Ph.D. The company continues to focus on developing antiviral treatments, supported by royalties from its collaboration with AbbVie for hepatitis C virus products.

Positive

• Presentation of new preclinical data for EDP-235 indicates potential advancements in COVID-19 treatment.
• EDP-235 is positioned as a once-daily oral antiviral, which may enhance patient compliance.
• Research funding from hepatitis C products may support further development of EDP-235.

Negative

• None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19, will be presented at the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)-World Health Organization Virtual Conference (WHO): COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment. The conference is being held virtually on October 19 – October 21, 2021.

Poster Presentation:
Date: October 19, 2021
Time: 8:00 a.m. CET
Poster #120: “EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19”
Presenter: Li-Juan Jiang, Ph.D.

Posters will be available to view on the conference platform during the conference and for three months thereafter. Further information about the ISIRV-WHO Virtual Conference 2021 can be found here.

About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005607/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What is EDP-235 and how does it relate to COVID-19?

EDP-235 is Enanta's lead oral protease inhibitor designed for the treatment of COVID-19, aiming to provide an antiviral option.

When will the data for EDP-235 be presented?

The new preclinical data for EDP-235 will be presented on October 19, 2021, at the ISIRV-WHO Virtual Conference.

Who is presenting the EDP-235 data at the conference?

Li-Juan Jiang, Ph.D., will present the data for EDP-235 at the conference.

What is the significance of the ISIRV-WHO Virtual Conference for Enanta?

The conference represents an opportunity for Enanta to share critical findings regarding EDP-235 and its potential impact on COVID-19 treatment.

How is Enanta funded for its research and development?

Enanta's research is funded through royalties from hepatitis C virus products developed under its collaboration with AbbVie.